SLC5A2 and neurodegenerative disease: This distribution suggests that SGLT2 inhibitors could have neuroprotective effects, highlighting the promising use for DGF and other SGLT2 inhibitors in treating neurodegenerative diseases (Sa-Nguanmoo et al. 2017).